AEZS
Dunno,
I'm completely unconcerned about cetrorelix or SPPI's product. Both are GnRH blockers (with serious limitations), both are injectables.
Cetrorelix, Lucrin, and other GnRH blockers have no chance whatsoever if Proellex makes it to market.
That said, I agree that AEZS appears to be a compelling investment, just not for cetrorelix in endometriosis. I'm going to do more DD.
I pulled my 17.99 GTC on RPRX. I believe the company should be valued at ~$20-$25 right now.